Toxic epidermal necrolysis is a rare condition involving the skin at the dermoepidermal junction, with possible inclusion of mucous membranes. The condition is associated with systemic toxicity and high mortality rates. Successful treatment requires optimization of local as well as systemic therapy. We report the case of a young woman who developed toxic epidermal necrolysis, possibly resulting from lamotrigine therapy. Local therapy included a combination of a biological cover and alginate together with a synthetic cover (Aquacel Ag®).

La nécrolyse épidermique toxique est une maladie rare touchant la peau à la jonction dermo-épidermique, avec inclusion possible des muqueuses. La condition est associée à une toxicité systémique et des taux de mortalité élevés. Le succès du traitement nécessite une optimisation de la thérapie locale ainsi que systémique. Nous rapportons le cas d’une jeune femme qui a développé une nécrolyse épidermique toxique, causée peut-être par un traitement par la lamotrigine. Le traitement local a compris une combinaison d’une couverture biologique et de l’alginate avec une couverture en matière synthétique (Aquacel Ag®).

Burn and Reconstructive Surgery Center University Hospital Brno Czech Republic

Burn and Reconstructive Surgery Center University Hospital Brno Czech Republic ; Medical School Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Lyell A. Toxic epidermal necrolysis: An eruption resembling scalding of the skin. Br J Dermatol. 1956;68:355–61. PubMed

Becker DS. Toxic epidermal necrolysis. Lancet. 1998;351:1417–20. PubMed

Atiyeh BS, Dham R, Yassin MF, El-Musa KA. Treatment of toxic epidermal necrolysis with moisture-retentive ointment: A case report and review of the literature. Dermatol Surg. 2003;29:185–8. PubMed

Murphy JT, Purdue GF, Hunt JL. oxic epidermal necrolysis. T J Burn Care Rehabil. 1997;18:417–20. PubMed

Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7. PubMed

Zajicek R, Matouskova E, Broz L, Kubok R, Wandauf P, Königova R. New biological temporary skin cover Xe-Derma® in the treatment of superficial scald burns in children. Burns. 2011;37:333–7. PubMed

Zajicek R, Pintar D, Broz L, Suca H, Königova R. Toxic epidermal necrolysis and Stevens-Johnson syndrome at the Prague Burn Centre 1998-2008. Journal of the European Academy of Dermatology and Venerology. 2012;26:639–43. PubMed

Chaloupková Z, Hokynková A, Lipový B, Kaloudová Y, Brychta P. Xe-Derma® - a temporary biological skin substitute in the treatment of burns. Hojení ran. 2012;6:3–5.

Ramakrishnan KM, Sankar J, Venkatraman J. Role of biological membranes in the management of Stevens Johnson syndrome, Indian experience. Burns. 2007;33:109–11. PubMed

Case Report: Wound Closure Acceleration in a Patient With Toxic Epidermal Necrolysis Using a Lyophilised Amniotic Membrane